Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma

Rafat Abonour, K. M. Scott, L. A. Kunkel, Michael Robertson, R. Hromas, V. Graves, E. N. Lazaridis, Larry Cripe, V. Gharpure, Christie Orschell, B. Mills, Edward Srour, Kenneth Cornetta

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

In the use of autologous PBPC transplantation in patients with multiple myeloma, contamination of PBPC with myeloma cells is commonly observed. Enrichment for CD34+ cells has been employed as a method of reducing this contamination. In this study the reduction of myeloma cells in PBPC was accomplished by the positive selection of CD34+ cells using immunomagnetic bead separation (Isolex 300 system). PBPC were mobilized from 18 patients using cyclophosphamide (4.5 g/m2) and G-CSF (10 μg/kg/day). A median of two leukaphereses and one selection was performed per patient. The median number of mononuclear cells processed was 3.50 x 1010 with a recovery of 1.11 x 108 cells after selection. The median recovery of CD34+ cells was 48% (range 17-78) and purity was 90% (29-99). The median log depletion of CD19+ cells was 3.0. IgH rearrangement, assessed by PCR, was undetectable in 13 of 24 evaluable CD34+ enriched products. Patients received 200 mg/m2 of melphalan followed by the infusion of a median of 2.91 x 106/kg CD34+ cells (1.00-16.30). The median time to absolute neutrophil count > 0.5 x 109/l was 11 days, and sustained platelet recovery of > 20 x 109/l was 14 days. We conclude that immunomagnetic-based enrichment of CD34+ cells results in a marked reduction in myeloma cells without affecting engraftment kinetics.

Original languageEnglish
Pages (from-to)957-963
Number of pages7
JournalBone Marrow Transplantation
Volume22
Issue number10
StatePublished - 1998

Fingerprint

Autologous Transplantation
Multiple Myeloma
Blood Cells
Immunomagnetic Separation
Leukapheresis
Melphalan
Granulocyte Colony-Stimulating Factor
Cyclophosphamide
Neutrophils
Blood Platelets
Cell Count
Polymerase Chain Reaction

Keywords

  • CD34 selection
  • Immunomagnetic separation
  • Multiple myeloma
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. / Abonour, Rafat; Scott, K. M.; Kunkel, L. A.; Robertson, Michael; Hromas, R.; Graves, V.; Lazaridis, E. N.; Cripe, Larry; Gharpure, V.; Orschell, Christie; Mills, B.; Srour, Edward; Cornetta, Kenneth.

In: Bone Marrow Transplantation, Vol. 22, No. 10, 1998, p. 957-963.

Research output: Contribution to journalArticle

@article{40c5edd352904f159d378af8df921d8b,
title = "Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma",
abstract = "In the use of autologous PBPC transplantation in patients with multiple myeloma, contamination of PBPC with myeloma cells is commonly observed. Enrichment for CD34+ cells has been employed as a method of reducing this contamination. In this study the reduction of myeloma cells in PBPC was accomplished by the positive selection of CD34+ cells using immunomagnetic bead separation (Isolex 300 system). PBPC were mobilized from 18 patients using cyclophosphamide (4.5 g/m2) and G-CSF (10 μg/kg/day). A median of two leukaphereses and one selection was performed per patient. The median number of mononuclear cells processed was 3.50 x 1010 with a recovery of 1.11 x 108 cells after selection. The median recovery of CD34+ cells was 48{\%} (range 17-78) and purity was 90{\%} (29-99). The median log depletion of CD19+ cells was 3.0. IgH rearrangement, assessed by PCR, was undetectable in 13 of 24 evaluable CD34+ enriched products. Patients received 200 mg/m2 of melphalan followed by the infusion of a median of 2.91 x 106/kg CD34+ cells (1.00-16.30). The median time to absolute neutrophil count > 0.5 x 109/l was 11 days, and sustained platelet recovery of > 20 x 109/l was 14 days. We conclude that immunomagnetic-based enrichment of CD34+ cells results in a marked reduction in myeloma cells without affecting engraftment kinetics.",
keywords = "CD34 selection, Immunomagnetic separation, Multiple myeloma, Transplantation",
author = "Rafat Abonour and Scott, {K. M.} and Kunkel, {L. A.} and Michael Robertson and R. Hromas and V. Graves and Lazaridis, {E. N.} and Larry Cripe and V. Gharpure and Christie Orschell and B. Mills and Edward Srour and Kenneth Cornetta",
year = "1998",
language = "English",
volume = "22",
pages = "957--963",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma

AU - Abonour, Rafat

AU - Scott, K. M.

AU - Kunkel, L. A.

AU - Robertson, Michael

AU - Hromas, R.

AU - Graves, V.

AU - Lazaridis, E. N.

AU - Cripe, Larry

AU - Gharpure, V.

AU - Orschell, Christie

AU - Mills, B.

AU - Srour, Edward

AU - Cornetta, Kenneth

PY - 1998

Y1 - 1998

N2 - In the use of autologous PBPC transplantation in patients with multiple myeloma, contamination of PBPC with myeloma cells is commonly observed. Enrichment for CD34+ cells has been employed as a method of reducing this contamination. In this study the reduction of myeloma cells in PBPC was accomplished by the positive selection of CD34+ cells using immunomagnetic bead separation (Isolex 300 system). PBPC were mobilized from 18 patients using cyclophosphamide (4.5 g/m2) and G-CSF (10 μg/kg/day). A median of two leukaphereses and one selection was performed per patient. The median number of mononuclear cells processed was 3.50 x 1010 with a recovery of 1.11 x 108 cells after selection. The median recovery of CD34+ cells was 48% (range 17-78) and purity was 90% (29-99). The median log depletion of CD19+ cells was 3.0. IgH rearrangement, assessed by PCR, was undetectable in 13 of 24 evaluable CD34+ enriched products. Patients received 200 mg/m2 of melphalan followed by the infusion of a median of 2.91 x 106/kg CD34+ cells (1.00-16.30). The median time to absolute neutrophil count > 0.5 x 109/l was 11 days, and sustained platelet recovery of > 20 x 109/l was 14 days. We conclude that immunomagnetic-based enrichment of CD34+ cells results in a marked reduction in myeloma cells without affecting engraftment kinetics.

AB - In the use of autologous PBPC transplantation in patients with multiple myeloma, contamination of PBPC with myeloma cells is commonly observed. Enrichment for CD34+ cells has been employed as a method of reducing this contamination. In this study the reduction of myeloma cells in PBPC was accomplished by the positive selection of CD34+ cells using immunomagnetic bead separation (Isolex 300 system). PBPC were mobilized from 18 patients using cyclophosphamide (4.5 g/m2) and G-CSF (10 μg/kg/day). A median of two leukaphereses and one selection was performed per patient. The median number of mononuclear cells processed was 3.50 x 1010 with a recovery of 1.11 x 108 cells after selection. The median recovery of CD34+ cells was 48% (range 17-78) and purity was 90% (29-99). The median log depletion of CD19+ cells was 3.0. IgH rearrangement, assessed by PCR, was undetectable in 13 of 24 evaluable CD34+ enriched products. Patients received 200 mg/m2 of melphalan followed by the infusion of a median of 2.91 x 106/kg CD34+ cells (1.00-16.30). The median time to absolute neutrophil count > 0.5 x 109/l was 11 days, and sustained platelet recovery of > 20 x 109/l was 14 days. We conclude that immunomagnetic-based enrichment of CD34+ cells results in a marked reduction in myeloma cells without affecting engraftment kinetics.

KW - CD34 selection

KW - Immunomagnetic separation

KW - Multiple myeloma

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031754533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031754533&partnerID=8YFLogxK

M3 - Article

C2 - 9849692

AN - SCOPUS:0031754533

VL - 22

SP - 957

EP - 963

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -